This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jarvis, S. C Search for Related Content Social Bookmarking                         What's this?

VALUE, blood pressure and diabetes — what can we learn?

Richford Gate Medical Practice, Richford Street, London, W6 7HY, UK, sarah.jarvis{at}gp-E85016.nhs.uk

With the introduction of the new GMS contract, GPs need to treat patients efficiently and effectively in order to achieve Quality and Outcomes Framework points. The VALUE trial has shown that aggressive treatment of hypertension minimises the risk of further cardiovascular outcomes. Dr Sarah Jarvis, a GP, notes that applying the results of this trial to clinical practice will help GPs reach their targets and protect hypertensive patients against further health risks such as new onset diabetes.

Key Words: VALUE trial • diabetes • hypertension • GMS contract.

References

• Investing in General Practice: The New General Medical Services Contract. BMA, February 2003.
• Department of Health. National Service framework for Diabetes. London 2003.
• National Institute of Clinical Excellence: Inherited clinical guideline -Management of type 2 diabetes: management of blood pressure and blood lipids. National Institute of Clinical Excellence, October 2002.
• Department of Health. National Service framework for Coronary Heart Disease. London 2001.
• Dickstein K. ELITE II and Val-HEFT are different trials: together what do they tell us? Curr Controls Trials Cardiovasc Med 2001; 2:240-3.[CrossRef]
• Pfeffer MA, Swedberg K., Granger CB et al. CHARM Investigators and Committees. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759-66.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Parving HH, Lehnert H., Brocher-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:910-12.[Free Full Text]
• Law MR, Wald NJ, Morris JK, Jordan RE Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003;326: 1427-31.[Abstract/Free Full Text]
• Julius S., Kjeldsen S., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;19:2022-31.
• Williams B., Poulter N., Brown MJ et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society - BHS IV. J Hum Hypert 2004;18:139-85.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Weber MA, Julius S., Kjeldsen SE et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet 2004;363:2049-51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Dahlof B., Devereux R., Kjeldsen S. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1010.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288:2981-97.[Abstract/Free Full Text]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 6, 418-420 (2004)
DOI: 10.1177/14746514040040061001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jarvis, S. C Search for Related Content Social Bookmarking                         What's this?